Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells

Inclusion Criteria: 1. 18-65 years old, regardless of sex; 2. Patients with lymphoma and multiple myeloma who need autologous hematopoietic stem cell transplantation; 3. KPS score ≥70; 4. creatinine clearance rate ≥ 50mL/min, total bilirubin level \< 1.5mg/dL, ALT and AST \< 2 times the upper limit of normal value; 5. Absolute neutrophil count (ANC)≥1.5×109/L, platelet count ≥80×109/L, Hb≥ 75g/L, WBC ≥ 3.0× 109/L; 6. Patients can tolerate chemotherapy; 7. No active infection before chemotherapy; 8. The patient voluntarily participated in this trial and signed the informed consent form; 9. The researcher thinks that the subjects can benefit. Exclusion Criteria: 1. Those who have previously received allogeneic or autologous hematopoietic stem cell transplantation; 2. Serious or uncontrolled virus infection: HIV, syphilis positive; 3. Severe dysfunction of internal organs; 4. severe mental or nervous system diseases; 5. allergic to PEG-rhG-CSF, rhG-CSF and other preparations or proteins expressed in Escherichia coli; 6. pregnant or lactating female patients; Women of childbearing age refuse to accept contraceptive measures; Those who plan to become pregnant during the study period; 7. The researcher judges other subjects who are not suitable to participate.